OCTREOTIDE ACETATE | N021008 | NOVARTIS PHARMACEUTICALS CORP
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Rakoczy Molino Mazzochi Siwik LLP FDA-2006-P-0331 · 6 docket documents Ben Venue Laboratories, Inc. and Sun Pharmaceuticals Industries Ltd. filed citizen petitions requesting that the FDA determine whether the discontinued formulation of Sandostatin (octreotide acetate injection) was withdrawn for reasons of safety or effectiveness under NDA 19-667, which the FDA grant | Other | 2009-04-20 | Partially Denied | Rakoczy Molino Mazzochi Siwik LLP |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$6948.08
per ea
Lowest NADAC/Unit
$3523.03
per ea
Brand NDCs
3
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00078082581SANDOSTATIN LAR DEPOT 30 MG KT | $6948.08 | EA | Brand | — | 2026-07-08 |
| 00078081881SANDOSTATIN LAR DEPOT 20 MG KT | $4588.55 | EA | Brand | — | 2026-07-08 |
| 00078081181SANDOSTATIN LAR DEPOT 10 MG KT | $3523.03 | EA | Brand | — | 2026-07-08 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.